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Background: Indeterminate pulmonary nodules in patients diagnosed with osteosarcoma present a challenge for accurate
staging and prognosis. The aim of this study was to explore the significance of this finding.
Methods: A retrospective cohort study of 120 patients with osteosarcoma was performed in the North East of England. Chest
computed tomographies (CTs) at presentation were reviewed and the incidence of ‘indeterminate’ nodules recorded. Follow-up
scans were reviewed and survival as well as prognostic features were analysed.
Results: 25% of our cohort presented with indeterminate nodules. Of these, 33% were subsequently confirmed as metastases, the
majority within a year. Kaplan–Meier survival analysis showed that patients with indeterminate nodules fared better than those with
frank metastatic disease, and similar to those who presented with a normal chest CT. We found no radiographic features that
predicted survival.
Conclusions: Indeterminate nodules remain a clinical and diagnostic dilemma. Close monitoring of patients is advised during the
first year from presentation, and there is potential for indeterminate nodules to develop into frank metastases later than five years
from presentation.
Sarcomas metastasise most frequently to the pulmonary parench-
yma. Computed tomography (CT) has become the standard for
detecting and monitoring pulmonary lesions, but frequently
identifies nodules of uncertain clinical significance. Often the
assumption is that, especially in children, these nodules represent
metastatic disease. However, up to 60% of pulmonary nodules
found in adults and 33% in children may be non-malignant
(Bearcroft and Davies, 1999; Picci et al, 2001).
Differentiating benign and malignant lesions is essential for
planning treatment and determining prognosis. When nodules are
detected, invasive procedures may be necessary to establish the
histopathologic diagnosis, but in many cases the nodules are
simply monitored with repeat CT scans. From the patients’
perspective, such nodules cause stress and concern as their
significance remains uncertain.
Osteosarcoma is the most common malignant bone tumour
arising in children and adolescents. Up to 20% of patients will
have synchronous metastatic pulmonary disease detectable
radiologically at initial presentation (Goorin et al, 1991). However,
the positive predictive value of radiographic criteria for pulmonary
nodules using CT has been estimated at 53% (Robertson et al, 1988).
Among patients with normal chest CTs on presentation, 20–25% will
relapse, usually in the lungs (metachronous metastatic pulmonary
disease). A cohort of these patients will have indeterminate
pulmonary nodules (IPNs) at presentation, the majority of which
will turn out to be malignant (Fernandez-Pineda et al, 2012).
Indeterminate pulmonary nodules are those that have some risk
of cancer. There remains controversy around their definition, but
in general IPNs fall under the category of non-calcified nodules.
Their diameters can vary but based on recent studies nodules
arising from a range of solid cancer types with a diametero10mm
have caused greatest discussion (Robertson et al, 1988; Rissing
et al, 2007; Nakamura et al, 2009, 2017).
Our institution performed a retrospective cohort study to
determine the significance upon survival of IPNs reported at initial
presentation on chest CT in patients diagnosed with osteosarcoma.
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Furthermore, we tried to characterise features of these nodules for
patients at risk. Our null hypothesis was that the presence of such
nodules had no effect on long-term survival when compared to a
non-metastatic group.
MATERIALS AND METHODS
Approval for this study was obtained by our NHS trust clinical
effectiveness committee, Caldicott number 7707. A retrospective
cohort study of 120 consecutive osteosarcoma patients treated
between 1998 and 2015 was performed using a regional database.
Patients underwent a CT scan as part of their initial staging studies
(Scanner Somatom Definition AS by Siemens, Erlangen,
Germany—3mm slices).
Data entered included age, anatomical site and histological type
of osteosarcoma.
The minimum follow-up was 2.5 months (average, 78 months;
median, 54 months; range, 2.5–243 months).
Computed tomography scans and reports were reviewed by two
authors (KMG and LL), who were blinded to the clinical outcome
of the patients. Patients were grouped into non-metastatic,
metastatic (synchronous) and indeterminate nodules. Indetermi-
nate pulmonary nodules were defined as non-calcified nodules
o10mm in maximal diameter (Rissing et al, 2007).
Follow-up CT scans usually performed every 4–6 months were
examined for the subgroup of patients with either no metastasis or
IPNs to record their radiological outcome as either stable or
metachronous disease (Figure 1).
Finally, the characteristics of IPNs were recorded including site
(central or peripheral), size (45mm), number (single or multiple)
and histological subtype of primary tumour.
Disease-free survival was undertaken via Kaplan–Meier survivor
analysis with failure defined as death. Censored observations were
defined by continuous disease-free survival at last follow-up.
Univariate analysis of factors affecting survival in those patients
with IPNs based on their radiological characteristics was
performed using Log-rank test (SPSS version 21, IBM Corporation,
Armonk, NY, USA)
For this study, significance was set at 0.05 and power 0.8.
RESULTS
One hundred and four out of 120 patients presenting with
osteosarcoma had full data sets available (86%). The median age at
presentation was 20 years (range, 7–72). Sixty-five (62%) tumours
were located in the lower limb, 14 (13%) upper limb, 11 (11%) axial
skeleton, 9 (9%) head and neck and 5 (5%) extraskeletal.
At initial staging, 55 (53%) patients presented with no
metastasis, nor IPNs, 19 (18%) patients presented with synchro-
nous metastatic disease (Supplementary Table) and 30 (29%)
patients presented with IPNs.
Of the patients who presented with IPNs, 20% (6 out of 30)
progressed to metastatic disease at the same site as the nodules,
mean age 15 (range, 7–20). 10% (3 out of 30) developed lung
metastasis at a separate site, mean age 21 (range, 16–25). In the
remaining 21 patients (70%), the radiological features remained
static, mean age 26 (range, 7–67).
The median time for patients presenting with IPNs to be
diagnosed with metastatic disease was 27 weeks (range, 9–297
weeks). Eighty per cent of this cohort was diagnosed within 1 year.
The 104 patients presenting with osteosarcoma were split into
three groups: non-metastatic; indeterminate pulmonary nodules and
frank pulmonary metastases. Overall, survival was significantly
different between patients presenting with metastatic pulmonary
disease vs those presenting with no evidence of metastases or IPNs
(Figure 2). In the 55 patients presenting with no evidence of
metastases, nor IPNs, 16 developed new frank metastatic pulmonary
lesions with only one long-term survivor following metastasectomy.
For patients presenting with IPNs, the groups were too small for
the time varying covariates to be calculated; therefore, the raw data
are presented demonstrating two early deaths in the group with
stable IPNs, both of which were due to extra-pulmonary disease
progression (Table 1A). For patients with IPNs that developed into
metastases, there was one survivor out of six patients. This survivor
underwent extensive right full pneumonectomy (Table 1B). This
group also contains a patient with IPNs that progressed into frank
metastases six years from presentation. In the remaining group
where patients developed frank metastases around the IPNs, there
was one survivor out of three. This survivor underwent a right
wedge resection for a rapidly growing single metastasis (Table 1C).
Univariate analysis of nodule characteristics (site, size, number
and location) found no prognostic indicators for survival (Table 2).
In a direct comparison of nodule size, three out of six patients who
developed metastasis at the same site as the nodule had an initial size
of over 5mm, compared to the static nodule group that had a rate of
2 from 21 patients with IPNs that were over 5mm (P¼ 0.014).
DISCUSSION
The purpose of this study was to evaluate whether IPNs were
associated with poorer survival in patients with osteosarcoma.
120 patients
104 patients with complete record
No lung mets (55) Indeterminate nodules (30) Lung mets (19)
Nodules     mets (6)Nodules static (21) Nodules + mets elsewhere (3)
Figure 1. Patient distribution.
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Furthermore, we aimed to ascertain whether radiological char-
acteristics of such nodules led to a poorer outcome. Our results
showed that patients presenting with IPNs had significantly better
survivorship to patients presenting with metastatic disease and
similar survivorship to patients with no lung metastasis. Nodules
that subsequently turned out to be metastasis tended to be larger
(45mm).
With the advent of fine slice CT, the incidence in detection of
subcentimetre nodules is increasing. Hanamiya et al (2012)
reported the rate of detection of non-calcified pulmonary nodules
to be 75% in patients with extra-pulmonary malignant tumours.
Understanding the significance of such nodules is difficult and only
a handful of studies have aimed to try and quantify their impact on
patient outcome. Rissing et al most notably performed a similar
study but looking prospectively at 331 patients with a range of
sarcoma types. In their cohort, 21% presented with IPNs (vs 29% in
this study). Twenty-eight per cent of IPNs progressed to metastatic
disease (vs 30% in this study). Metastatic disease tended to develop
at the site of the original IPNs (90 vs 66% in this study). They also
found that those IPNs that did progress to metastasis did so within
the first year. In contrast, they found nodules 45mm were
associated with a poorer prognosis, whereas our study found no
such association (Rissing et al, 2007). This may be as a result of
fewer numbers as there was an association with larger nodules
(45mm) being more prevalent at the site of subsequent metastatic
disease.
Brader et al acknowledged that no algorithm existed for making
the distinction between benign and malignant pulmonary nodules
based on just radiological findings in paediatric patients with
sarcomas. In their retrospective study of 30 paediatric osteosar-
coma patients, radiologists correctly identified 94% of the
malignant nodules. However, of the benign nodules, 11–30% were
correctly classified and 54–65% were deemed indeterminate. They
found only two radiological parameters consistently useful for
predicting malignancy—calcification and size 45mm (Brader
et al, 2011). Other studies have focused more towards the
significance of small or solitary nodules. Nakamura et al performed
a retrospective cohort study on 206 patients with a range of
sarcoma types. Their group found a statistically significant
relationship between the size of the pulmonary nodules and
cumulative overall survival. Patients with nodules o5mm in size,
showed overall survival similar to those that presented with a
normal chest CT. However, neither nodule number, location nor
tumour of origin was found to be of prognostic value. In their
study, all nodules were classified as either metastatic or benign,
with no mention of IPNs (Nakamura et al, 2009).
Indeterminate pulmonary nodules present a continued diag-
nostic dilemma for a large range of solid cancers and there is a
clear paucity in the literature guiding best practice in their
management. In terms of lung cancer, the American College of
Chest physicians recommended follow-up scans vs PET-CT or
tissue diagnosis of suspicious nodules on the basis of probability.
These take into account amongst others, a number of time-
dependent factors such as biomarkers, volumetric analysis and
growth rate. Yet, such studies cannot provide the answer the
patients want at the time of discovery (Pinsky et al, 2014; Massion
and Walker, 2014; Gould et al, 2013).
Our study has a number of limitations. This is a retrospective
study with a relatively small patient group, where incomplete data
sets resulted in a large amount of censored data. Despite this,
follow-up data were available for as far out as 14 years and our
study represents the largest series we know of assessing the survival
outcome of osteosarcoma patients presenting with IPNs. CT scans
were reported by experienced musculoskeletal radiologists but may
be prone to inter- and intra-observer error, which was not
evaluated. Computed tomography scanning technology had
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Figure 2. This graph shows three super-imposed Kaplan–Meier survivorship curves for patients with osteosarcoma. Green represents those
patients who presented with no metastasis or indeterminate nodules. Yellow represents those patients with indeterminate nodules and blue are
those patients with metastasis at presentation. No significant difference in survivorship was noted between those with indeterminate nodules and
those without metastasis at presentation. Survivorship in the metastatic group was significantly worse (Po0.001). A full colour version of this figure
is available at the British Journal of Cancer journal online.
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improved over the study period and undoubtedly would have led
to increased sensitivity and specificity when diagnosing IPNs. The
effect of neo-adjuvant chemotherapy was not included in this
analysis; however, standard treatment protocols were followed as
per regional guidelines and in keeping with most surveillance
studies (Daw et al, 2015).
In conclusion, IPNs remain a diagnostic dilemma for the
clinician and patient. Lack of understanding with regard to the
significance of these nodules at initial presentation makes for a
difficult consultation. In our series, overall survival was signifi-
cantly better for patient presenting with IPNs than those with
metastatic disease. Most of those that progressed to metastatic
Table 1A. Stable indeterminate nodules
Age
(years) Primary site
Survival
(days) Histological subtype
IPN
number
IPN
distribution
Size over
5mm
Pulmonary
metastasectomy
10 Distal femur Alive (5456) Osteoblastic Solitary Peripheral No No
13 Clavicle Alive (5031) Chondroblastic Solitary Peripheral No No
17 Proximal tibia Alive (4902) Osteoblastic Solitary Peripheral No No
64 Great toe Alive (4345) Atypical high grade Solitary Central No No
13 Distal femur Alive (4362) Chondroblastic Multiple Peripheral No No
19 Distal femur Alive (4053) Chondroblastic Solitary Central Yes No
14 Distal tibia Alive (3312) Osteoblastic Solitary Peripheral No No
15 Distal femur Alive (3123) Osteoblastic and chondroblastic Multiple Central No No
35 Skull Alive (2144) Parosteal low grade Solitary Peripheral No No
35 Skull Alive (2073) Atypical high grade Solitary Peripheral No No
23 Ulna Alive (2229) Periosteal chondroblastic
intermediate grade
Solitary Peripheral No No
59 Maxilla Alive (2541) Osteoblastic and chondroblastic Solitary Peripheral No No
15 Proximal tibia Alive (2398) Osteoblastic Multiple Peripheral No No
19 Distal femur Alive (1973) Chondroblastic Solitary Peripheral No No
19 Proximal tibia Alive (1508) Periosteal chondroblastic
intermediate grade
Multiple Peripheral No No
19 Distal femur Alive (461) Osteoblastic and chondroblastic Multiple Peripheral No No
15 Proximal tibia Alive (623) Osteoblastic Solitary Peripheral No No
26 Proximal
fibula
Alive (405) Osteoblastic Multiple Central No No
24 Proximal
humerus
Alive (195) Chondroblastic Multiple Peripheral No No
56 Proximal
femur
Deatha (981) Osteoblastic Solitary Peripheral Yes No
67 Kidney Deatha (139) Atypical high grade Solitary Peripheral Yes No
Abbreviation: IPN¼ indeterminate pulmonary nodules.
aThese patients died of extensive local recurrence.
Table 1B. Indeterminate nodules develop into metastases
Age
(years) Primary site
Survival
(days)
Histological
subtype
IPN
number
IPN
distribution
Size over
5mm
Pulmonary
metastasectomy
20 Distal femur (Li Fraumeni
syndrome)
Alive (5905) High grade Multiple Peripheral Yes Yes
11 Distal femur Death (3901) High grade Solitary Central Yes Yes
7 Distal femur Death (803) Osteoblastic Solitary Peripheral Yes Yes
19 Distal femur with skip lesion Death (504) Osteoblastic Solitary Peripheral No No
16 Distal femur Death (987) Osteoblastic Multiple Peripheral No Yes
15 Proximal humerus Death (319) Osteoblastic Multiple Peripheral No Yes
Abbreviation: IPN¼ indeterminate pulmonary nodules.
Table 1C. Metastases develop around indeterminate pulmonary nodules
Age
(years)
Primary
site
Survival
(days)
Histological
subtype
IPN
number
IPN
distribution
Size over
5mm
Pulmonary
metastasectomy
22 Distal femur Alive (5238) Chondroblastic Multiple Peripheral No Yes
25 Distal femur Death (4401) Osteoblastic Solitary Peripheral No Yes
16 Mandible Death (874) Atypical high grade Multiple Peripheral No No
Abbreviation: IPN¼ indeterminate pulmonary nodules.
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disease did so within the first year although one patient did
progress at a later stage, 6 years from presentation. Our series of
IPN patients that developed metastases also contains two long-
term survivors following metastasectomy. As such, we would
recommend close observation with at least annual CT imaging for
all patients for up to 10 years, particularly for larger nodules
(45mm). Multicentre studies need to be performed and data
pooled in order to provide better prognostic information and
standardised care. Improved imaging techniques, such as MRI/
PET, that may give radiologists the ability to enhance metastatic
lesions to distinguish them from benign nodules is an important
area for further research.
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Table 2. Univariate analysis of prognostic variables for
indeterminate nodules (Log-rank test)
Variable Significance (P value) Survival range (days)
45mm 0.530 803–4053
Multiple nodules 0.559 319–5905
Central location 0.873 405–4345
Chondroblastic 0.081 461–5238
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